Skip to main content

Research Repository

Advanced Search

A new soluble and bioactive polymorph of praziquantel

Zanolla, Debora; Perissutti, Beatrice; Passerini, Nadia; Chierotti, Michele R.; Hasa, Dritan; Voinovich, Dario; Gigli, Lara; Demitri, Nicola; Geremia, Silvano; Keiser, Jennifer; Cerreia Vioglio, Paolo; Albertini, Beatrice

Authors

Debora Zanolla

Beatrice Perissutti

Nadia Passerini

Michele R. Chierotti

Dritan Hasa

Dario Voinovich

Lara Gigli

Nicola Demitri

Silvano Geremia

Jennifer Keiser

Paolo Cerreia Vioglio

Beatrice Albertini



Abstract

Praziquantel is the only available drug to treat Schistosomiasis. However, its utilization is limited by many drawbacks, including the high therapeutic dose needed, resulting in large tablets and capsules difficult to be swallowed, especially from pediatric patients. In this study, an alternative option to overcome these disadvantages is proposed: to switch to a novel crystalline polymorph of racemic compound praziquantel. The preparation of the crystalline polymorph was realized via a neat grinding process in a vibrational mill. The new phase (Form B) was chemically identical to the starting material (as proved by HPLC, 1H NMR, and polarimetry), but showed different physical properties (as evaluated by SEM, differential scanning calorimetry, thermogravimetry, ATR-FTIR spectroscopy, X-ray powder diffraction, and solid-state NMR). Furthermore, the crystal structure of the new phase was solved from the powder synchrotron X-ray diffraction pattern, resulting in a monoclinic C2/c cell and validated by DFT-D calculation. Moreover the simulated solid-state NMR 13C chemical shifts were in excellent agreement with the experimental data. The conversion of original praziquantel into Form B showed to affect positively the water solubility and the intrinsic dissolution rate of praziquantel. Both the in vitro and in vivo activity against Schistosoma mansoni were maintained. Our findings suggest that the new phase, that proved to be physically stable for at least one year, is a promising product for designing a new praziquantel formulation.

Citation

Zanolla, D., Perissutti, B., Passerini, N., Chierotti, M. R., Hasa, D., Voinovich, D., Gigli, L., Demitri, N., Geremia, S., Keiser, J., Cerreia Vioglio, P., & Albertini, B. (2018). A new soluble and bioactive polymorph of praziquantel. European Journal of Pharmaceutics and Biopharmaceutics, 127, 19-28. https://doi.org/10.1016/j.ejpb.2018.01.018

Journal Article Type Article
Acceptance Date Jan 29, 2018
Online Publication Date Jan 31, 2018
Publication Date 2018-06
Deposit Date Nov 18, 2024
Journal European Journal of Pharmaceutics and Biopharmaceutics
Print ISSN 0939-6411
Electronic ISSN 1873-3441
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 127
Pages 19-28
DOI https://doi.org/10.1016/j.ejpb.2018.01.018
Keywords Praziquantel, Mechanochemistry, Solid-state reactions, Polymorphism Solubility, Bioactivity, Crystal structure solution, DFT-D calculations, Neglected tropical diseases
Public URL https://nottingham-repository.worktribe.com/output/42198739
Publisher URL https://www.sciencedirect.com/science/article/pii/S0939641117309323?via%3Dihub